An AHH-1 TK +/ " cell derivative was developed that stably expresses human cytochrome P4501B1 (CYP1B1) cDNA in an extrachromosomal vector which confers resistance to 1-histidinol and co-expresses NADPH cytochrome P450 oxidoreductase (OR). The CYPlBl-expressing cell line was designated hlBl/OR. Microsomes prepared from CYP1B1 cDNA expressing cells exhibit elevated levels of 7-ethoxyresorufin deethylase (EROD), 7-ethoxy-4-trifluoromethylcoumarin deethylase (EFCD), benzo(a)pyrene hydroxylase (BPH), bufuralol 1'-hydroxylase, testosterone hydroxylase activities and spectrally quantifiable cytochrome P450. CYPlBl-containing microsomes did not contain detectable coumarin 7-hydroxylase, p-nitrophenol hydroxylase, lauric acid hydroxylase, (S)-mephenytoin 4'-hydroxylase or diclofenac 4'-hydroxylase activities. Kinetic parameters for selected substrates were compared among CYP1B1 and the two additional members of the CYP1 family, CYP1A1 and CYP1A2. For BPH and EFCD, the rank order of rates of substrate metabolism were CYP1A1>CYP1B1> CYP1A2. For EROD, the rank order of substrate metabolism was CYP1A1>CYP1A2>CYP1B1. For both EROD and EFCD the apparent K m values for CYP1B1 were more similar to CYP1A1 than to CYP1A2. In order to begin to characterize the promutagen activating ability of CYP1B1, the mutagenicity of selected chemicals was examined in hlBl/OR cells; there was increased sensitivity (CYP1B1-expressing relative to control cells) to the mutagenicity of benzo(a)pyrene, cyclopenta(c/f)pyrene, 4-(methylnitrosamino)-l-(3-pyridyl)-l-butanone and aflatoxin B! (AFB). CYP1B1, expressed in this system, appears to be particularly efficient at activating AFB.
Introduction
Cytochromes P450 (CYP) are a family of haemoproteins which are the principal enzymes involved in the activation of many promutagens and procarcinogens (Guengerich, 1988; Gonzalez, 1989; Gonzalez and Gelboin, 1994) . These enzymes are expressed in many tissues in vivo with the highest levels of this class of enzymes found in the liver of mammals (Gonzalez and Gelboin, 1994) . Individual cytochrome P450 forms have unique, yet often overlapping substrate specificity. For example, at least five different hepatic cytochrome P450 forms have been reported to activate aflatoxin B] (AFB) (Aoyama et al, 1990 ) and 4-(methylnitrosamino)-l-(3-pyridyl)-l-butanone (NNK) (Crespi et al, 1991b; Smith et al, 1992) . Aromatic amines are usually activated by a single form (CYP1A2) (Butler et al, 1989) .
One of the more recently identified human cytochrome P450 forms, CYP1B1, was first recognized as being 2,3,7,8,-tetrachlorodibenxo-/>-dioxin (TCDD)-inducible in human keratinocytes (Sutter et al, 1994) . The CYP1B1 protein is also expressed in MCF-7 cells upon treatment with TCDD (Spink et al, 1994) . Northern analysis of RNA isolated from different human tissues reveals that CYP1B1 is expressed in the kidney, prostate, uterus and mammary tissues, but at much lower levels in the liver (Sutter et al, 1994) . Mouse CYP1B1 (P450EF) is expressed in C3H 10T1/2 cells (Shen et al, 1994; Savas et al, 1994) . Rat CYP1B1 is expressed at high levels in the adrenal gland of untreated rats (Otto et al, 1991; Walker et al, 1995) and in many additional tissues upon TCDD treatment. The significance of CYP1B1 in xenobiotic metabolism, in general, and procarcinogen metabolism, in particular, is not well understood.
In addition to CYP IB 1, the CYP1 family contains two additional members, CYP1A1 and CYP1A2. CYP1A1 has been recognized as having a principal role in the metabolic activation of many polycyclic aromatic hydrocarbons (PAH) (Shimada et al, 1992) and CYP1A2 has been recognized a principal role in the activation of many aromatic and heterocyclic amines (Butler et al, 1989; Eaton et al, 1995) . CYP1A2 is primarily a hepatic enzyme, whereas, CYP1A1 and CYP1B1 appear to be principally extrahepatic and most readily detected following administration of inducers (Sesardic et al, 1990; Sutter et al, 1994) .
Here we report the development of a human cell line stably expressing CYP1B1 cDNA. This cell line, designated hlBl/ OR, metabolizes prototypic substrates for CYP1 and contains spectrophotometrically quantifiable and immunologically detectable CYP1B1 protein. The AHH-1 TK +/ " human Blymphoblastoid cell line, which was used in these studies, is a convenient vehicle to measure the induction of gene mutations at the hypoxanthine phosphoribosyl transferase (hprt) and thymidine kinase loci and also the induction of chromosomal aberrations, aneuploidy and micronuclei (Crespi et al, 1987; Crespi etal, 1991a; Crofton-Sleigh etal, 1993) . The CYP1B1 cDNA-expressing cell lines were characterized and used to study the P450 form-specific activation of mutagens at the hprt locus. Finally, we have compared properties of cDNAexpressed CYP1B1 with cDNA-expressed CYP1A1 and CYP1A2.
Material and methods
Cells, tissue culture, DNA introduction AHH-1 TK +/ " human B lymphoblastoid cells were maintained in Roswell Park Memorial Institute (RPMT) medium 1640 supplemented to 9% v/v with horse serum. Plasmid vector was introduced into AHH-1 TK +A~ cells by electroporation using a BTX model 600 Electro cell Manipulator (San Diego, CA, USA). Cells containing vectors were initially selected by resistance to hygromycin B, then shifted l-histidinol-selection to accomplish vector amplification. Cells bearing recombinant plasmids were maintained in medium either with 100-400 Hg/ml hygromycin B or without histidine and containing 2 mM 1-histidinol (pEBVHistk-based vectors) (Crespi et al, 1990a) .
Enzymes and reagents
Restriction endonucleases, Klenow fragment of DNA polymerase I and T4 DNA ligase were purchased from New England Biolabs (Beverly, MA, USA). 7-Ethoxy-4-trifluoromethylcoumarin and 7-hydroxy-4-trifluoromethylcoumarin were purchased from Molecular Probes, Eugene, OR, USA NNK and 3-hydroxybenzo(a)pyrene were obtained from the NCI Chemical Carcinogen Repository (Research Triangle Park, NC, USA). Radiolabelled lauric acid and (S)-mephenytoin were obtained from Amersham, Arlington Heights, IL, USA. All other chemicals were purchased from Sigma Chemical Company, St. Louis, MO, USA.
Cytotoxicity and mutagenicity assays
Cytotoxicity was estimated by measuring cell growth after treatment. After cultures have resumed exponential growth, the cumulative growth of the mutagen-treated cultures was divided by the cumulative growth of the negative control cultures to yield relative survival. Induction of mutation at the hprt locus was measured by previously published protocols (Crespi et al, 1987) with minor modifications Human lymphoblasts were exposed to the mutagen for 28 h. cDNA-derived NADPH cytochrome P450 oxidoreductase (OR) is expressed from the glucocorticoid-Lnducible mouse mammary tumour virus long terminal repeat. OR expression was increased by the addition of 1 nM dexamethasone. Each replicate culture contained 3X10 7 cells. After a 7 day phenotypic expression period, the mutant fraction was measured by plating 7.5 X10* cells in three 96-well microtitre plates in the presence of 6-thioguanine (0.6 (ig/ml) and 500 cells in two 96-well microtitre plates without selection. NNK was dissolved in water for delivery to the cell cultures all other chemicals were dissolved in dimethyl sulphoxide (DMSO)
DNA manipulations, vectors
Bacterial transformations, plasmid DNA isolations and construction of the expression vectors were performed according to standard protocols. For CYP1B1 expression, a derivative of the pRedHyHo vector (Crespi et al, 1995) , designated pBlueHyHo was used. pBlueHyHo was produced from pRedHyho by introduction of the LacZ a complementation from pUC19 into the HindlK site between the HisD expression unit and the OR expression unit. This construct was performed as follows: the polyhnker in pUC19 was eliminated by digestion with EcoRl, treatment with the Klenow fragment of DNA polymerase, then digestion with Hind\U and blunt end religation after treatment with mung bean nuclease. The LacZ a complementation was isolated by digestion with £co0109I and BsfBl and made blunt ended by treatment with the Klenow fragment of DNA polymerase. This fragment was blunt-end ligated into gel-punfied, single cut pRedHyHo which had been subjected to HindMl partial digestion and treatment with the Klenow fragment of DNA polymerase and calf intestine phosphatase.
The CYP1B1 cDNA was first introduced into the unique Xbal site of the pBlueHyHo vector as a 1.7 kb f/mdlll/Ssp I fragment of pl28 (containing the entire, unmodified, native open reading frame (Sutler et al, 1994) ) modified by the addition of Xbal linkers. Vector containing the cDNA in the appropriate orientation was identified by restriction mapping and designated pBlueHyHolBl (Figure 1) .
Preparation of microsomal samples
Microsomes were prepared according to (Penman and Crespi, 1987) . For microsomes used in spectral studies, cells were incubated in the presence of 20 u.g/ml 5-aminolevulinic acid and 0.2% DMSO and 1 |iM dexamethasone for 2 days prior to microsome preparation. Microsomal protein concentrations were determined by the method of (Lowry et al, 1951) using bovine serum albumin as the standard. Cytochrome P450 difference spectra were performed according to (Omura and Sato, 1964 ) using a Beckman Model 640 spectrophotometer (Beckman Instruments, Fullerton, CA, USA).
Enzyme assays
Benzo(a)pyrene hydroxylase (BPH) activity was measured according to (Nebert and Gelboin, 1968) and quantified using 3-hydroxybenzo(a)pyrene as standard. Benzo(a)pyrene (BP) was used at a final concentration of 25 nM. The other enzyme assays were conducted according to the following methods: 7-cthoxyresorufin O-deethylase (EROD, Burke et al, 1977 ), 7-ethoxy^»-trifluoromethylcoumarin O-deethylase (EFCD, DeLuca et al, 1988 , cytochrome c reductase (Phillips and Langdon, 1962) , coumarin 7-hydroxylase (Greenlee and Poland, 1978) , bufuralol r-hydroxylase(Kronbachera/., 1987), diclofenac 4'-hydroxylase (Leeman et al., 1993) , p-nitrophenol hydroxylase (Reinke and Moyer, 1985) , lauric acid hydroxylase (Clarke ex al, 1994) and (5>mephenytoin 4'-hydroxylase (Wrighton et al, 1993) . NNK metabolism was analysed as previously described (Smith et al, 1992) . Apparent K,,, and v mM values were calculated by non-linear kinetics using GraFit 3.0 (Erithacus Software, Middlesex, UK)
Antibodies and immunoblot detection
Amino terminal-hexa-histidine-tagged fusion polypeptide corresponding to human CYP1B1 ammo acid residues 166-349 (Sutter et al, 1994) was produced in Escherichia coli using the inducible expression vector, pTrcHis (Invitrogen Corp., San Diego, CA, USA). After cell lysis, the hexa-histidinetagged proteins were purified by affinity chromatography (Hochuli, 1990) , using a nickel-nitrilotriacetic acid agarose column according to the manufacturer's procedure (Qiagen Inc., Chatsworth, CA, USA). After elution from the column, these proteins were further purified by preparative sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). The denatured polypeptides were recovered by electrophoretic elution and dialysed against 0.5 X phosphate-buffered saline (N J.Walker, F.G.Crofts, and T.R.Sutter, unpublished results).
Male New Zealand White rabbits were immunized with the purified polypeptides according to the procedures of Spring Valley Laboratories (Sykesville, MD, USA). Serum was prepared from blood drawn 4 weeks after the second boost. Microsomal proteins were separated by SDS-PAGE (Laemmli, 1970) , electroblotted (Towbin et al, 1979) , and incubated with anti-CYP serum at a dilution of 1:5000. Detection was by the enhanced chemiluminescence system (Amersham Life Sciences) after incubation with horseradish peroxidase conjugated goat anti-rabbit immunoglobulin (Ig)G secondary antibody, Promega, (Madison, WI, USA) at a dilution of 1:20 000.
Results and discussion

Cell line development/characterization
Human lymphoblastoid cell lines were developed to constitutively express transferred human CYP1B1. Vector-bearing, 1-histidinol-resistant, clonal populations were isolated by plating in 96-well microtitre plates at limiting cell dilution. Seven clonal populations were assayed for sensitivity to BP cytotoxicity (BP concentrations ranged from 3 to 100 ng/ml, exposure time, 4 days). All populations had similar activities (range ~2-fold) and one population was chosen for further characterization and designated hlBl/OR cells.
The stability of cDNA-derived enzymatic activity in hlBl/ OR cells was monitored as a function of time of growth in cell culture. Cells were propagated and monitored periodically for sensitivity to BP cytotoxicity. The cell line was stable for at least 2 months of continuous exponential growth. This level of stability is sufficient for most applications in toxicology and drug metabolism (Crespi et al., 1991a) .
Characterization of the enzyme
Microsomes prepared from hlBl/OR cells contained spectrophotometrically and immunologically detectable CYP1B1 protein. This protein was not detectable in control cells (without cDNA-bearing vector) (Figure 2 ). The level of expression (spectral P450 content) under culture conditions similar to those used in the mutagenicity assay was 14 pmol P450/mg microsomal protein. This content is slightly lower than that previously reported forCYPlAl (hlAlv2 cells, 25 pmol P450/ mg) and CYP1A2 (hlA2v2 cells, 38 pmol P450/mg). No spectrally active CYP was detectable in control microsomes CYP1A1 or CYP1A2 were not detectable by Western blot at loading up to 150 ^g/lane (data not shown).
The level of OR activity, as measured by cytochrome c reductase, was elevated ~ 1.5-fold relative to microsomes prepared from control cells. We have found that when cytochrome P450 and OR cDNAs are co-expressed from a single vector, the levels of OR present can vary substantially for different P450 cDNAs. The results for CYP1B1 are at the low end of the range. For example, when CYP2C9/OR or CYP2E1/OR are co-expressed, the level of cytochrome c reductase activity is higher [250 or 80 nmol/(mg min) respect- +/ " cells is not saturating, therefore, the level of OR can affect the rate of cytochrome P450 metabolism and hence, should be considered when interpreting data on rates of metabolism. For the comparisons made below, the other cytochrome P450 cDNAs were expressed in cells with native OR levels. Therefore, we would expect that the slightly higher OR levels with CYPIBI will increase the rate of metabolism somewhat, but the magnitude of the effect should be small (<2-fold).
Analysis of metabolism of a panel of cytochrome P450 substrates which microsomes prepared from CYP1B1-expressing cells revealed elevated EROD, EFCD, BPH (Table I) , bufuralol 1 '-hydroxylase and testosterone hydroxylase (Table II) . No detectable coumarin 7-hydroxylase, /?-nitrophenol hydroxylase, lauric acid hydroxylase, (S)-mephenytoin 4'-hydroxylase or diclofenac 4'-hydroxylase activities were present.
The lack of coumarin 7-hydroxylase, a reaction catalysed by CYP2A6 (Yamano et al., 1990) , p-nitrophenol hydroxylase, a reaction catalysed by CYP2A6 and CYP2E1, lauric acid hydroxylase a reaction catalysed by CYP4A and CYP2E1 (Clarke et al, 1994) , (5)-mephenytoin 4'-hydroxylase, a reaction catalysed by CYP2C19 (Wrighton et al, 1993) and diclofenac 4'-hydroxylase, a reaction catalysed by CYP2C9 (Leeman et al, 1993) were consistent with the enzymeselective nature of these substrates and supports the prediction of activities based on comparisons of CYPIBI primary amino acid sequence to those of CYP1A1 and CYP1A2 (Sutter etal, 1994) .
The detection of bufuralol 1'-hydroxylase and testosterone hydroxylase activities were surprising. The rates of metabolism per unit enzyme were relatively low (~300-fold lower than CYP2D6/bufuralol or CYP3A4/testosterone) but the metabolite signal was substantially (10 fold) above machine background and/or incubations with control microsomes. CYPlBl-catalysed bufuralol 1'-hydroxylase activity was not inhibited by the addition of 1 ^M quinidine, a CYP2D6-selective inhibitor (data not shown) indicating that the metabolism was not due to presence of CYP2D6. Concurrent incubations with cDNAexpressed CYP2D6 with and without 1 fiM quinidine showed 95% inhibition. With CYPIBI, two hydroxylated testosterone metabolites were observed. These metabolites co-chromato- Kinetic analyses were performed in CYPIBI, CYP1A1 and CYP1A2 microsomes. Incubations were performed in duplicate in at least two independent experiments with five to nine substrate concentrations. All activities (except EROD) were not detectable in control microsomes. Control microsomes had EROD activity of 1 pmole/(mgXmin). Turnover of selected substrates were analysed in microsomes prepared from hlBl/OR cells. Activities are expressed as either nmol product per mg min (cytochrome c reductase) or turnover number (pmol product per pmol P450) The level of cytochrome c reductase activity in control microsomes was 28 nmol/(mg min) None of the cytochrome P450-associated activities were detectable in control microsomes.
graphed with authentic 6P-hydroxytestosterone and 16a-hydroxytestosterone and were formed in approximately equimolar quantities. Unfortunately, the levels of metabolite production by CYPIBI were too low to allow isolation of sufficient metabolite for mass spectral analysis. Therefore, the identity of these metabolites should be regarded as tentative. The testosterone metabolites produced by CYPIBI did not coelute with authentic 2a-, 6a-, 7a-, lla-, 14a-, 15a-, 2(i-, 11(3-or 16P-hydroxytestosterone standards.
Testosterone 6P-hydroxylation is considered to be a prototypical CYP3A reaction. In order to test for any contribution of CYP3A to the observed 6P-hydroxylase activity, inhibition by troleandomycin was analysed (Chang et al, 1994) . CYPIBIcatalysed testosterone hydroxylase activity was not inhibited by 25 jiM troleandomycin (95% activity of control) while cDNA-expressed CYP3A4 was inhibited by troleandomycin to 58% of the activity of control. Therefore, presence of CYP3A4 was not responsible for the observed 6P-hydroxylation of testosterone.
There is often considerable substrate overlap among the different enzymes comprising the CYP1 family. Indeed, relatively high levels of metabolite formation were observed with CYP1B1 for EROD, EFCD and BPH which are known CYP1A substrates. In order to further characterize these reactions, we examined kinetic constants for three model substrates for CYP1A1, CYP1A2 and CYPIBI (Table I ). The apparent Yf or CYPlBl-catalysed EROD was 60 nM, which is quite similar to the apparent K™ for CYP1A1 (64 nM) and lower than the K^, for CYP1A2 (230 nM). The turnover number for CYPIBI (1.1/min) was lower than for either CYP1A1 (7.1/ min) or CYP1A2 (2.0/min). The slightly higher OR levels present in CYPIBI microsomes should not have affected this 86 rank order. The apparent K^ for CYPIBI-catalyzed EFCD was 580 nM, which is similar to the apparent K m for CYP1A1 (1100 nM) and much higher than the K,,, for CYP1A2 (4.8 nM). The turnover number for CYPIBI (0.74/min) was lower than for either CYP1A1 (11/min) orCYPlA2 (0.9/min). The slightly higher OR levels present in CYPIBI microsomes again should not have affected this rank order. BPH activity was measured at a single substrate concentration (25 \\M). The turnover number at this concentration for CYPIBI (0.27/min) was intermediate relative to CYP1A1 (1.0/min) or CYP1A2 (0.007/ min). The slightly higher OR levels present in CYPIBI microsomes should not have affected this rank order.
Mutagenicity assays
The ability of cDNA-derived CYP1B1 to activate promutagens was examined using hlBl/OR cells. Four promutagens, benzo(a)pyrene (BP), cyclopenta(c,d)pyrene (CPP), AFB and NNK were examined for the ability to induce gene locus mutations at the hprt locus. We, and others, have previously demonstrated that AFB and NNK are activated by multiple CYP forms (Shimada and Guengerich, 1989; Forrester et al, 1990; Aoyama et al, 1990; Crespi et al, 1991b,c; Smith etal, 1992) . The polycylic aromatic hyrdocarbons (PAH), BP and CPP are prototypical CYP1A1 substrates (Penman et al, 1994) .
BP was clearly mutagenic to hlBl/OR cells (Figure 3 ). BP induced a monotonic increase in mutant fraction in the concentration range 10-1000 ng/ml. Over this same concentration range BP is non-mutagenic to control cells (Penman et al, 1994) . BP was relatively toxic to hlBl/OR cells. Comparison of this dose-response data with that previously published for CYP1A1 (Penman et al, 1994) and taking into consideration that the hlAl and hlBl/OR cell lines have roughly comparable cytochrome P450 contents, indicates that CYPIBI and CYP1A1 have roughly comparable abilities to activate BP to a gene mutagen. The slightly higher OR levels present in hlBl/OR cells should not affect this conclusion. The activation of BP by CYPlBl-expressing human lymphoblasts stands in contrast to the lack of a response induced by BP with CYP1B1 present in the Salmonella typhimurium umu gene expression system (Shimada et al, 1996) . The bacterial system does indicate that both CYP1A1 and CYP1A2 are capable of activating BP, therefore, the difference cannot be completely attributed to a lack of sensitivity of the system to this compound. The activation of BP by CYPIBI in human lymphoblasts is consistent with the detection of BP metabolites by fluorometric assay (Table I) , although the phenols detected by this assay are not expected to be directly mutagenic. Metabolism of BP by CYP1A1 and CYP1A2 expressed in human lymphoblasts was also detectable (Table I ). The discordance between the systems cannot be attributed to the presence of microsomal epoxide hydrolase in human lymphoblasts (and Relative survival data are plotted as the mean only. The dotted line is the 99% upper confidence limit from the historical negative control data base at the hprt locus (a measure of statistical significance) The mean and SEM for the negative controls were 1.8X1CT 6 and 0.6XKT 6 respectively (n = 12).
its absence in the bacterial system) since the lymphoblastoid cell line does not have detectable microsomal epoxide hydrolase activity (Crespi et al, 1985) . In contrast to BP, several BP diols produced a detectable response with CYP1B1 in the S.typhimurium umu gene expression system (Shimada et al, 1996) . Therefore, different responses of BP in the two systems could be due to differences in sensitivity of the different host cells to the range of electrophiles produced by BP metabolism. Additional experiments are required to clarify this point.
CPP was also clearly mutagenic to hlB I/OR cells (Figure 3) . A monotonic increase in mutant fraction was observed over the concentration range 5-60 ng/ml. CPP was non-mutagenic to control cells over the concentration range tested (Penman et al, 1994) . Like BP, CPP is relatively toxic to hlBl/ OR cells. Comparison of this dose-response data with that previously published for CYP1A1 (Penman et al, 1994) and taking into consideration that the hlAl and hlBl/OR cell lines have similar cytochrome P450 contents, indicates that as with BP, CYP1B1 and CYP1A1 have roughly comparable abilities to activate CPP to a gene mutagen. The slightly higher OR levels present in hlBl/OR cells should not affect this conclusion. Further analysis, with metabolite analyses and epoxide hydrolase co-expression may reveal more pronounced differences between CYP1B1 and CYP1A1 for this substrate.
AFB induced a monotonic increase in mutant fraction over the concentration range 1-10 ng/ml (Figure 3) . AFB was toxic to hlBl/OR cells. The response of control cells to AFB has been previously reported four times (Crespi and Thilly, 1984; Crespi et al, 1990a Crespi et al, ,b, 1991c . In these reports AFB was nonmutagenic to control cells at exposure concentrations up to 1000 ng/ml. Comparison of this dose-response data with that previously published for CYP1A1 (Penman et al, 1994) , CYP1A2 (Crespi etal, 1991c) , CYP2A6 (Crespi etal, 1990a) , CYP3A4 (Crespi et al, 1991c) indicate that CYP1B1 is among the most efficient enzymes for activating AFB to a gene mutagen. Relevant parameters are summarized in Table HI . We have listed the minimum effective concentration of AFB (A in Table HI) which was calculated as the point where the concentration-response curve crosses the 99% upper confidence limit from the historical negative control data base (a mutant fraction 7X10" 6 , all cell lines appear to have similar negative control mutant frequencies). Comparison of these values indicates the relative sensitivities of the different cell lines to AFB mutagenicity. However, the cell lines have different cytochrome P450 contents (B in Table HI ) and the effect of increasing cytochrome P450 content is to shift the cellular concentrationresponse curve to lower concentrations (Crespi et al, 1990a; Penman et al, 1994) . Therefore, a comparison of the abilities of the different enzymes to activate AFB should consider the differences in P450 contents. The parameter of the minimum effective concentration multiplied by the cytochrome P450 content (AXB in Table IH) should be proportional to the intrinsic ability of the enzyme to activate AFB. With this analysis, the abilities of CYP1A2 and CYP1B1 are similar (about two-fold). CYP1A1, CYP2B6 and CYP2A6 are -10-20-fold less active than CYP1B1 and CYP3A4 is about fivefold less active than CYP1B1. The slightly higher OR levels present in hlBl/OR cells should not affect this conclusion.
The efficient activation of AFB by CYP1B1 -expressing human lymphoblasts stands in sharp contrast to the complete lack of a response induced in the S.typhimurium umu gene expression system (Shimada et al, 1996) . This bacterial system does give positive responses for AFB when either CYP1A1 and CYP1A2 are present. However, the difference in response between CYP1A1 and CYP1A2 is less pronounced in the S.typhimurium system relative to the human lymphoblast system (three-fold versus 40-fold; Penman et al, 1994) and substantially higher AFB concentrations were needed to generate a relatively weak response in S.typhimurium. It is possible that CYP1B1 is a relatively low capacity enzyme for AFB activation and insufficient electrophillic metabolite is formed to generate a detectable response in S.typhimurium. Further experiments are needed to clarify this point.
AFB is a known human (and rat) hepatocarcinogen and it has been established that among the mixture of enzymes present in human liver, CYP1A2 appears to be the most important enzyme at low AFB concentrations (Eaton et al, 1995) , although CYP3A4 may be involved at high AFB exposures. Given the extrahepatic nature of CYP1B1, one would expect little role of this enzyme in hepatic AFB activation. However, it is possible that CYP1B1 may play a role in extrahepatic AFB activation, particularly for individuals exposed to inducers.
NNK induced a monotonic increase in mutant fraction over the concentration range 10-100 ^g/ml (Figure 3) . NNK was also toxic to hlBl/OR cells. NNK is non-toxic and nonmutagenic to control cells at exposure concentrations up to 300 (ig/ml (Crespi et al, 1991b) . We had previously demonstrated that multiple human P450 forms can activate NNK (Crespi et al, 1991b; Penman et al, 1994) . After allowing for differences in cellular P450 content (using the same approach used for AFB above), the ability to metabolically activate NNK is approximately CYP1A1 = CYP1A2 = CYP1B1 = CYP2A6 > CYP2E1 = CYP2D6. It is interesting to note that, per unit induced mutant fraction, NNK is much more toxic The data for all other cytochrome P450s is taken from (Crespi et al, 1990a; Penman et al, 1994) Survival data were grouped in increments of 10% decreases in survival and the induced mutant fractions for the individual cell lines were averaged.
to CYPlBl-expressing cells than to cells expressing other cytochrome P450 enzymes (Figure 4) . NNK is an asymmetric nitrosamine and this observation may be indicative of a different pathway of metabolism for CYPIBI than for CYP1A1, CYP1A2, CYP2A6, CYP2D6 or CYP2E1. In order to test this hypothesis, NNK metabolism was analysed in microsomes prepared from hlBl/OR cells. Unfortunately, when sodium bisulphite (5 mM) was added to the incubation mixture to trap the keto aldehyde, thereby allowing quantification of the two cc-hydroxylation pathways (Peterson et al, 1991) , the metabolism of NNK was inhibited by 50%. Therefore, sodium bisulphite was not added to the assay mixtures, and the metabolite peak was quantified as a mixture of keto aldehyde and keto alcohol. The apparent Kn, and V^ values were 1.2 mM and 1.8/min respectively. The apparent K^ value for CYPIBI was 3-10-fold higher than that reported for CYP2D6 (Penman et al, 1993) , CYP1A2 (Smith et al, 1992) or CYP2A6 (Patten et al., 1996) . Since humans are exposed to low levels of NNK, and CYPIBI exhibited a high K^, other cytochrome P450s, such as CYP2A6, may play a more important role in the activation of NNK in vivo. With regard to activation of other nitrosamines, A'-nitrosodimethylamine was negative for CYPIBI activation using the S.typhimurium umu gene expression system (Shimada et al, 1996) . Therefore, it is unclear how broadly CYPIBI activates nitrosamines.
The development of the hlBl/OR cell line complements the other isogenic AHH-1 TK +/~ human B-lymphoblastoid cell lines expressing human cytochromes P450 (Crespi et al, 1990a (Crespi et al, ,b, 1991c Penman et al, 1993 Penman et al, , 1994 . For all of these expressed human P450s, spectrophotometric determination of P450 content is possible, allowing comparisons of metabolism and protoxin activation on both a per cell and per pmole P450 basis. This enables a quantitative analysis of the relative efficiency of different P450 enzymes to carry out specific biotransformations in an intact cellular system. The present study, in combination with the study by (Shimada et al, 1996) indicate that CYPIBI activates a broad range of structurally diverse procarcinogens including, polycyclic aromatic hydrocarbon (and dihydrodiol derivatives), aromatic amines and amides, heterocyclic amines, nitro polycyclic aromatic hydrocarbons, AFB and NNK. This broad substrate specificity, coupled with the expression of CYPIBI in multiple human tissues (Sutter et al, 1994; Shimada et al, 1996) , suggests that CYPIBI could have a significant role in cancer induction in humans. The striking differences in response for the activation of BP and AFB in the S.typhimurium umu gene expression system and human lymphoblasts serves to underscore the need to test procarcinogens in multiple systems.
